The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET, DCE-MRI and molecular biomarkers for early prediction of nonprogression in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab.
Matthias Scheffler
No relevant relationships to disclose
Marc Christiaan Allardt Bos
No relevant relationships to disclose
Martin L. Sos
No relevant relationships to disclose
Lukas Carl Heukamp
Consultant or Advisory Role - Qiagen
Honoraria - Roche
Lucia Nogova
Consultant or Advisory Role - Roche
Honoraria - Roche
Katharina Koenig
No relevant relationships to disclose
Masyar Gardizi
No relevant relationships to disclose
Christian Mattonet
No relevant relationships to disclose
Deniz Kahraman
No relevant relationships to disclose
Carsten Kobe
No relevant relationships to disclose
Ronald Boellaard
No relevant relationships to disclose
Adriaan A. Lammertsma
No relevant relationships to disclose
Thorsten Persigehl
No relevant relationships to disclose
Walburga Engel-Riedel
Consultant or Advisory Role - Roche
Karin Toepelt
Other Remuneration - Roche
Bernd Neumaier
No relevant relationships to disclose
Reinhard Büttner
Honoraria - Lilly; Merck; Novartis; Pfizer; Qiagen; Roche
Thomas Zander
Consultant or Advisory Role - Roche
Honoraria - Roche
Juergen Wolf
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche